$IMRX

24/7 Wall St. lists Thursday analyst calls. JPMorgan upgraded Charles River Laboratories (CRL) to Overweight, target $310. Wolfe raised Global Payments (GPN) to Outperform, target $110. Argus upgraded Roper Technologies (ROP) to Buy, target $450. Piper cut AppLovin (APP) to Neutral, target $385, and HubSpot (HUBS) to Neutral, target $220. Several other upgrades, downgrades, and initiations are noted.

Immuneering Corp (IMRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 imrx-20260805xexx991.htm EX-99.1 Document Exhibit 99.1 Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates - 17.3 month median overall survival in 55 first-line pancreatic cancer patients treated with atebimetinib in combination with

Zeskind Benjamin J. (PRESIDENT AND CEO) purchased 2,400 shares of Immuneering Corp (IMRX) at $4.56 on 2026-06-23.

Hall Brett Matthew (CHIEF SCIENTIFIC OFFICER) purchased 6,035 shares of Immuneering Corp (IMRX) at $4.15 on 2026-06-15.

Immuneering Corp (IMRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. imrx-20260611 0001790340 FALSE 0001790340 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K __________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

Immuneering Corp (IMRX) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. imrx-20260611 0001790340 FALSE 0001790340 2026-06-11 2026-06-11 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K __________________________________ CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report

Immuneering (NASDAQ:IMRX) reported updated Phase 2 results for atebimetinib plus modified gemcitabine nab-paclitaxel in first-line pancreatic cancer. CEO Ben Zeskind said median overall survival was 17.3 months in the original (n=34) cohort and remained 17.3 months in an expanded (n=55) cohort; Phase 3 MAPKeeper 301 is recruiting, with first dosing planned for mid-2026 and topline in 2028.

Immuneering (IMRX) reported updated Phase 2a data at ASCO for atebimetinib plus modified gemcitabine/nab-paclitaxel in 55 first-line metastatic pancreatic cancer patients. Median overall survival was 17.3 months vs 8.5 months in the MPACT standard-of-care study, with 8.3-month PFS, 82% disease control, and 36% ORR. Grade 3+ treatment-related AEs were limited to two chemotherapy-related categories; 84% maintained/gained weight at 3 months. MAPKeeper 301 Phase 3 is recruiting, with first dosing ex

Immuneering Corporation (IMRX) is a clinical-stage oncology company listed on Nasdaq, focused on developing Deep Cyclic Inhibitors (DCIs) for cancer treatment. Its lead product candidate, atebimetinib, targets MAPK pathway-driven tumors, including pancreatic cancer and NSCLC, and is currently in Phase 1/2a clinical trials with a planned Phase 3 registrational trial. The company has secured patent exclusivity for atebimetinib until 2042 and actively engages in collaborations and regulatory discussions with the FDA and EMA to advance its pipeline.

This page provides investors with the latest news and updates on Immuneering Corporation (IMRX), a clinical-stage biopharmaceutical company focused on oncology and neurology therapeutics. The content covers scientific progress, strategic partnerships, regulatory developments, and financial updates, with a particular focus on their lead drug candidate, atebimetinib, for pancreatic cancer. Recent news highlights include clinical trial results, financial reporting, and leadership appointments.